Amygdalin reduces lipopolysaccharide-induced chronic liver injury.

PMID: 

Artif Cells Nanomed Biotechnol. 2019 Dec ;47(1):2688-2697. PMID: 31257932

Abstract Title: 

Amygdalin reduces lipopolysaccharide-induced chronic liver injury in rats by down-regulating PI3K/AKT, JAK2/STAT3 and NF-κB signalling pathways.

Abstract: 

This study was aimed to evaluate the anti-inflammatory potential of AG on lipopolysaccharide (LPS) -induced liver injury and investigate the underlying mechanism. Administration of LPSs in the rat produced rat liver injury model which was ascertained at histological and molecular levels. Those models were treated with a range of doses of LPSs (0.5, 1.0 and 1.5 mg/kg body weight), followed by measurement physical parameter and function of the liver. Within the max treatment doses, no toxicity was shown but protective effects of AG were evidenced by regulation of physical parameters and functions of the liver. Interestingly, nuclear factor kappa B (NF-κB) levels and inflammatory factors were down-regulated by AG. Furthermore, the histopathological analysis demonstrated that AG promoted recovery from dysfunction of liver tissue in the rats, which was further confirmed by observing expression changes of inflammation-associated proteins. Particularly, alteration in the PI3K/AKT and JAK2/STAT3 signalling pathway protein expression were regulated by AG in a dose-dependent manner, indicating the mechanism underlying the relief effect of AG in liver injury. Our study demonstrated the potential of AG in the management of complications related to liver injury.

read more

Published by Taylor Mercado

Health Time is a blog talking about alternative medicines. And a blog founded by Taylor Mercado. She is a biologist and also a herbalist. This blog will help you and giving you tips regarding with herbal medicines.

Leave a comment

Design a site like this with WordPress.com
Get started